Soberana Plus

Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.[1]

Soberana Plus
A vial of Soberana Plus
Vaccine description
TargetSARS-CoV-2
Vaccine typeConjugate
Clinical data
Trade namesPasteur
Other namesFINLAY-FR-1A
Routes of
administration		Intramuscular
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019

2020

2021
Locations
By country and territory

By conveyance
International response

National responses
Medical response

Vaccines
Variants
Variants of concern

Other variants
Economic impact and recession

By country
Impacts
 COVID-19 portal

Medical uses

It can be used as a third (booster) dose for Soberana 02 vaccine at eight weeks.[2][3][4] It's also studied as an independent single-dose vaccine.[1][5][6]

Efficacy

It combined the Soberana 02, the vaccine booster shot shows an efficacy of 91.2%.[7]

Clinical trials

Booster dose
Further information: Soberana 02 § Clinical trials

Soberana Plus has also been studied as a booster dose for Soberana 02.[8][9]

Single dose
Clinical trials of single-dose Soberana Plus
Phase Registration Number of participants Age of participants
ID Date Total Vaccine Control
I RPCEC00000349 2021-01-05 30 30 0 18-55 years
IIa RPCEC00000366 2021-04-09 20 20 0 19-80 years
IIb 430 Placebo-controlled

Authorizations

On 20 August 2021, Cuba approved the Soberana Plus for booster.[10]

See also

References
  1. Cuban Registry of Clinical Trials. "SOBERANA PLUS". Retrieved 2021-09-08.
  2. "ماجرای تزریق اشتباهی واکسن کرونا" [The story of the wrong injection of the corona vaccine]. Iranian Students' News Agency (ISNA) (in Persian). 2021-08-31. Retrieved 2021-09-08.
  3. Cuban Registry of Clinical Trials. "SOBERANA 02-FaseIII". Retrieved 2021-09-08.
  4. "IRCT | Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years". www.irct.ir. Retrieved 2021-09-08.
  5. Cuban Registry of Clinical Trials. "SOBERANA 01B". Retrieved 2021-09-08.
  6. Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macias-Abraham C, Rodriguez-Noda L, Valenzuela-Silva C, et al. (2021). "A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial". medRxiv. doi:10.1101/2021.02.22.21252091. S2CID 232093115.
  7. "Cuba says second COVID-19 vaccine Soberana 2 boasts 91.2% efficacy". Reuters. Retrieved 2021-09-23.
  8. "SOBERANA 02-FaseIII". Retrieved 2021-09-09.
  9. "IRCT | Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years". en.irct.ir. Retrieved 2021-09-07.
  10. Dönmez BB (21 August 2021). "Cuba grants emergency use to 2 virus vaccines". Anadolu Agency. Retrieved 23 September 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.